ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results Read more about ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering Read more about ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis Read more about ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023 Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress Read more about ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease Read more about European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity Read more about ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD) Read more about ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target Read more about ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease Read more about European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
